Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: A meta-analysis

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages

  Shi Xia, Xu ^a   Hai Qin, Xu ^a   Xian Hua, Tang ^a   Bo, Feng ^a   Xiang Feng, Tang ^a  

^a NAVY GENERAL HOSPITAL   (China)

Author keywords

Condition regimen; Meta analysis; Reduced intensity; Survival; Transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CANCER PATIENT; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 79953325503     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01361.x     Document Type: Article

References (56)

1. Bortin MM, Horowitz MM, Rowlings PA et al. Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993: 12: 97.
2. Goldman JM, Horowitz MM. The international bone marrow transplant registry. Int J Hematol 2002: 76(Suppl 1): 393.
3. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001: 97: 3390.
4. Shimoni A, Kroger N, Zabelina T et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005: 19: 7.
5. Tsirigotis P, Bitan RO, Resnick IB et al. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 2006: 91: 852.
6. Slavin S, Nagler A, Shapira MY, Aker M, Gabriel C, Or R. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol 2002: 22: 64.
7. Mohty M, Fegueux N, Exbrayat C et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001: 28: 335.
8. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997: 315: 629.
9. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000: 56: 455.
10. Imataki O, Ohnishi H, Ohbayashi Y et al. Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen. Int J Clin Oncol 2009: 14: 197.
11. Satwani P, Baldinger L, Freedman J et al. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009: 15: 1587.
12. Ringdén O, Labopin M, Ehninger G et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009: 27: 4570.
13. Peres E, Braun T, Krijanovski O et al. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant 2009: 44: 579.
14. Andersson I, Ahlberg K, Stockelberg D, Brune M, Persson LO. Health-related quality of life in patients undergoing allogeneic stem cell transplantation after reduced intensity conditioning versus myeloablative conditioning. Cancer Nurs 2009: 32: 325.
15. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008: 14: 236.
16. Tomblyn M, Brunstein C, Burns LJ et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008: 14: 538.
17. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008: 26: 455.
18. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008: 111: 446.
19. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007: 109: 3588.
20. Kim I, Lee KH, Choi Y et al. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci 2007: 22: 227.
21. Faber E, Koza V, Vitek A et al. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning-a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007: 54: 443.
22. Graef T, Vaupel M, Fenk R et al. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol 2007: 25: 170.
23. Kim I, Yoon SS, Lee KH et al. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies. Clin Transplant 2006: 20: 496.
24. Shimoni A, Hardan I, Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006: 20: 322.
25. Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006: 108: 836.
26. Rodriguez R, Nademanee A, Ruel N et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006: 12: 1326.
27. Martino R, Parody R, Fukuda T et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006: 108: 2928.
28. Zambelli A, Lilleri D, Pedrazzoli P et al. Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies. Biol Blood Marrow Transplant 2005: 11: 423.
29. Massenkeil G, Nagy M, Neuburger S et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005: 36: 683.
30. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005: 19: 2304.
31. Valcárcel D, Martino R, Sureda A et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005: 74: 144.
32. Kim DH, Sohn SK, Baek JH et al. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005: 113: 220.
33. Omazic B, Hentschke P, Näsman-Björk I et al. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens. Scand J Immunol 2005: 61: 72.
34. Remberger M, Sundberg B. Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation. Haematologica 2004: 89: 710.
35. Saito T, Kanda Y, Nakai K et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003: 32: 601.
36. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003: 102: 756.
37. Schetelig J, Oswald O, Steuer N et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003: 32: 695.
38. Nachbaur D, Larcher C, Kircher B et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003: 82: 621.
39. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991: 28: 250.
40. Sullivan KM, Mori M, Sanders J et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992: 10: 127.
41. Satwani P, Harrison L, Morris E, DelToro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantationin adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005: 11: 403.
42. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998: 16: 2817.
43. Slavin S, Nagler A, Naparstek E et al. Nonmyeloblative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998: 91: 756.
44. Meijer E, Dekker A, Lokhorst H, Petersen E, Nieuwenhuis H, Verdonck L. Low incidence of infectious complications after nonmyeloablative compared with myeloablative stem cell transplantation. Transpl Infect Dis 2004: 6: 171.
45. Dreger P, Brand R, Milligan D et al., on behalf of the Chronic Leukaemia Working Party of the EBMT. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukaemia: a population-matched analysis. Leukemia 2005: 19: 1029.
46. Levine J, Uberti J, Ayash L et al. Lowered intensity preparative regimen for allogeneic stem cell transplantation delays acute graft versus host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003: 9: 189.
47. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995: 86: 2041.
48. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997: 15: 433.
49. Misawa M, Kai S, Okada M et al. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow. Int J Hematol 2006: 83: 74.
50. Jiménez M, Martínez C, Ercilla G et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol 2005: 33: 1240.
51. Ferrara JL, Cooke KR, Pan L, Krenger W. The immuno-pathophysiology of acute graft-versus-host-disease. Stem Cells 1996: 14: 473.
52. Perez-Simon JA, Diez-Campelo M, Martino R et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005: 130: 394.
53. Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50years of age. Blood 2005: 105: 1810.
54. Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003: 31: 1089.
55. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002: 99: 4357.
56. Nakamae H, Kirby KA, Sandmaier BM et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009: 15: 694.